Sign in
Active, not recruitingPhase 2/3

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Key facts

Who runs it
JCR Pharmaceuticals Co., Ltd.
Where
Japan20 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
27 people enrolled
Started
1 Sept 2019
Expected to end
31 Mar 2030
Type of study
Interventional
Treatments tested
  • JR-141
Record updated
3 September 2026

Who can take part

Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • A patient who participated in the preceding Study JR-141-301 and completed the Week 52 visit, and has no safety concerns to enter this study in the opinion of the investigator or subinvestigator
  • A patient capable of providing written informed consent in person (However, this is not required for patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with MPS II whose willingness cannot be verified.)
  • For patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with MPS II whose willingness cannot be verified, written consent must be obtained from the legally acceptable representative. (Wherever possible, written consent of the patient should be obtained.)
  • Male patient whose partner is of child-bearing potential and agrees to use a medically accepted, highly effective method of contraception

Who cannot take part

  • A patient who used any concomitant medication or therapy that could affect study assessments in the opinion of the investigator or subinvestigator
  • A patient with a history of serious drug allergy or hypersensitivity that precludes participation in this study in the opinion of the investigator or subinvestigator
  • A patient judged to be ineligible by the investigator or subinvestigator for other reasons

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.

The group in the trial

  • JR-141Treatment being tested

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 September 2026